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Neurodegenerative diseaseBecause of the increasing evidence that H63D HFE polymorphism appears in higher frequency in neurode-
generative diseases, we evaluated the neurological consequences of H63D HFE in vivo using mice that carry
H67D HFE (homologous to human H63D). Although total brain iron concentration did not change
signiﬁcantly in the H67D mice, brain iron management proteins expressions were altered signiﬁcantly. The
6-month-old H67D mice had increased HFE and H-ferritin expression. At 12 months, H67D mice had
increased H- and L-ferritin but decreased transferrin expression suggesting increased iron storage and de-
creased iron mobilization. Increased L-ferritin positive microglia in H67D mice suggests that microglia in-
crease iron storage to maintain brain iron homeostasis. The 6-month-old H67D mice had increased levels
of GFAP, increased oxidatively modiﬁed protein levels, and increased cystine/glutamate antiporter (xCT)
and hemeoxygenase-1 (HO-1) expression indicating increased metabolic and oxidative stress. By 12 months,
there was no longer increased astrogliosis or oxidative stress. The decrease in oxidative stress at 12 months
could be related to an adaptive response by nuclear factor E2-related factor 2 (Nrf2) that regulates antioxi-
dant enzymes expression and is increased in the H67D mice. These ﬁndings demonstrate that the H63D
HFE impacts brain iron homeostasis, and promotes an environment of oxidative stress and induction of adap-
tive mechanisms. These data, along with literature reports on humans with HFE mutations provide the
evidence to overturn the traditional paradigm that the brain is protected from HFE mutations. The H67D
knock-in mouse can be used as a model to evaluate how the H63D HFE mutation contributes to neurodegen-
erative diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
HFE polymorphisms are common allelic variants in Caucasians,
particularly in Northern European (1:200–400) and Irish (1:100)
populations. HFE protein interacts with the transferrin receptor
(TfR) and regulates transferrin-mediated iron uptake [1,2]. Two com-
mon HFE polymorphisms, H63D and C282Y, result in loss of ability to
limit iron uptake via TfR. The C282YHFE, generally associatedwith he-
reditary hemochromatosis (HH), is relatively rare (1.9%) while the
H63D HFE (8.1%) is more common in the general population [3,4]. Al-
though the penetrance of H63D HFE for HH is lower than the C282Y
HFE, the H63D HFE variant is associated with increased serum trans-
ferrin saturation, increased serum ferritin level and increased serum
iron level particularly in elderly populations (>55 years) and in
some of the demographic subgroups such as Mexican-Americanrgery, The Pennsylvania State
110), Hershey, PA 17033-0850,
r), eneely@psu.edu
du (J.R. Connor).
rights reserved.[5–7]. This biochemical penetrance of the H63D allele resulted in our
investigations into the relationship between the H63D HFE genotype
and late onset neurodegenerative diseases [8] where increased brain
iron is often reported [9,10].
The HFE protein is expressed in endothelial cells, choroid plexus
and the ependymal cells where it can inﬂuence brain iron content
[11]. However, based on misinterpretation of studies in the mid-
1900s, the brain is thought to be protected from iron overload associ-
ated with HFE mutations. However, these studies in the mid-1900s
[12,13] and recent MRI studies [14–16] all demonstrate an iron accu-
mulation in the brain of HH-patients; including those areas protected
by the blood–brain-barrier. Moreover, in healthy aged individuals the
presence of H63D HFE and transferrin C2 is associated with higher
brain ferritin iron [17]. Increased hippocampal and basal ganglia
iron is associated with poor declarative and verbal working memory
[18]. However, Jahanshad et al. [19] recently reported a positive asso-
ciation between H63D HFE and white matter ﬁber integrity in healthy
adults.
A relationship between iron accumulation and neurodegenera-
tive disease is established [9,10] so it was logical to consider a rela-
tionship between HFE genotypes and neurodegenerative diseases.
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have given mix results although most studies report either a rela-
tionship or a trend for H63D HFE to impact the disease particularly
in the presence of the ApoE4 mutation [8,20]. In amyotrophic lateral
sclerosis (ALS), the data are more consistent that H63D HFE is a risk
factor [8] although recent reports did not ﬁnd an association [21,22].
However, in a recent study [21] control subjects were pooled from
ﬁve published studies which could be problematic because frequen-
cy of HFE genotype is region dependent. Nonetheless, these studies
still reported, as the others, as many as 30% incidence of H63D HFE
in the ALS population [21,22].
Thus, to determine the speciﬁc effects of H63D HFE on phenotypes
we have developed cell models [23] and, in this paper, introduce an an-
imal model, which carries an analogous HFEmutation (H63D HFE). In a
human neuroblastoma cell line expressing different HFE genotypes, the
H63D cells have increased iron, oxidative stress [23] and endoplasmic
reticulum stress [24], increased glutamate release and monocyte
chemoattractant protein-1 secretion [25,26] and tau phosphorylation
[27]; each of which is proposed as a contributing factor to neurodegen-
erative diseases. Thus, we hypothesized that H63D HFE enables a con-
vergence of mechanisms that promote pathogenic processes.
In this study, we generated in vivomodel, a H67D knock-in mouse
line (mouse homolog of the human H63D), to evaluate the neurolog-
ical consequences of H63D HFE in vivo under controlled environmen-
tal conditions. We demonstrated that H63D HFE alters brain iron
homeostasis and creates an environment of oxidative stress. In the
long-term H67D mice will serve as a model to explore how H63D
HFE impacts disease mechanisms and therapeutic interventions in
neurodegenerative disorders.
2. Material and methods
2.1. Generation of H67D knock-in mice
The H67D knock-in mice (mouse homologous to H63D in
humans) were commercially generated (inGenious Targeting Labora-
tory, Inc, NY) as previously described by Tomatsu et al. [28]. Brieﬂy,
the HFE gene isolated from 129/SvJ mouse bacterial artiﬁcial chromo-
some library was subcloned into the pBS vector. The H67D point mu-
tation (199C to –G) was introduced into exon 2 of HFE gene by
site-directed mutagenesis, which destroyed a BspHI restriction site.
The HFE gene fragment containing H67D mutation was added be-
tween the thymidine kinase (TK) and neor gene of a targeting vector
(pPNT–loxP2 vector). The resulting targeting vector was linearized
with NotI and introduced into the 129/Sv-derived embryonic stem
(ES) cell line RW4 (Incyte Genomics Systems, St. Louis) by electropora-
tion. ES clones that were resistant to both 200 μg/ml G418 (BIBCO/BRL)
and 2 μM ganciclovir (Syntex Chemicals, Boulder, CO) were isolated
and used for injection into C57BL/6J blastocysts. Chimeric males were
bred to C57BL/6J females for germ-line transmission. The F1 heterozy-
gous mice were bred to Cre mice to remove neor gene ﬂanked by loxP
sites. The resultant neor-excised heterozygotes were interbred to gen-
erate wild-type (+/+), heterozygous (+/H67D) and homozygous
(H67D/H67D) H67D knock-in mice.
Mice were maintained under normal housing conditions. They
were given ad libitum access to rodent chow pellets and water. Both
males and females were included in all experiments. All procedures
were conducted according to the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Pennsylvania State
University College of Medicine Institutional Animal Care and Use
Committee.
2.2. Mice genotyping
DNA was isolated from tail biopsies according to DNeasy blood and
tissue kit (QIAGEN, CA). To amplify HFE gene including the H67Dvariant PCR analysis was conducted using a forward primer (5′AGG
ACTCACTCTCTGGCAGCAGGAGGTAACCA3′) and a reverse primer
(5′TTTCTTTTACAAAGCTATATCCCCAGGGT3′). PCR conditions were:
94 °C for 15 min, 94 °C for 45 s, 58 °C for 45 s, 39 cycles of 72 °C for
90 s and 72 °C for 10 min. Ampliﬁed PCR fragments were digested
with BspHI restriction enzyme for 2 h at 37 °C to detect H67D point mu-
tation. DNA fragmentswere separated by2% agarose gel electrophoresis.
2.3. Measurement of iron
Brain and liver samples were harvested from 6- and 12-month-
old wild-type (+/+), heterozygous (+/H67D) and homozygous
(H67D/H67D) H67D knock-in mice. Samples were diluted 1:10
(wt:v) with 0.32 M sucrose and homogenized. Total brain and hepatic
iron concentrations (μg/g of tissue; wet weight) were measured tripli-
cate by graphite furnace atomic absorption spectrometry (model
5100AA, Perkin-Elmer, Norwalk, CT) according to standard protocol
[29].
2.4. Immunblotting
Brain and liver tissues from 6- and 12-month-old wild-type (+/+),
+/H67D andH67D/H67Dmice (n=4–6/genotype)were homogenized
in homogenization buffer: 1× PBS, 0.5%NP-40 (IGEPAL; Sigma, St. Louis,
MO) and protease inhibitor cocktail (1:100; Sigma, St. Louis, MO). The
total protein concentration was determined with Pierce BCA protein
assay kit (Thermo scientiﬁc, MA). Total brain or liver homogenates
(20 μg) were separated by electrophoresis in Criterion polyacrylamide
Tris–HCl gel (4–20%; Bio-Rad, Hercules, CA). Proteins were then trans-
ferred to nitrocellulose membranes and the membranes were blocked
with 5%nonfat drymilk for 1 h at room temperature. After overnight in-
cubation at 4 °C with primary antibodies, membranes were then incu-
bated with enhanced chemiluminescent (ECL) anti-host horseradish
peroxidase-linked secondary antibodies (Amersham Bioscience,
Piscataway, NJ) for 1 h at room temperature. The signal was visualized
by ECL detection (Perkin Elmer, Waltham, MA) and Multigauge soft-
ware (V3.0; Fuji ﬁlm system) was used to quantitate the intensity of
the band. Following primary antibodies were used: HFE (1:500; Sigma,
St. Louis, MO), H-ferritin (1:1000; Covence, Princeton, NJ), L-ferritin
(1:500; abcam, Cambridge, MA), transferrin receptor (1:500;; Zymed
Laboratories Inc., San Francisco, CA), divalent metal transporter-1
(1:1000; Convence, Princeton, NJ), transferrin (1:1000; MP biomedi-
cals, Solon, OH), T cell immunoglobulin and mucin domain-containing
protein-2 (Tim-2; 1:2000; abcam, Cambridge, MA), cystine/glutamate
antiporter (xCT; 1:500; abcam, Cambridge, MA), hemeoxygenase-1
(HO-1; 1:500; Enzo Life Science, Farmingdale, NY), Nrf2 (1:1000;
abcam, Cambridge, MA), GFAP (1:2000; Dako, Carpinteria, CA) and
beta-actin (1:3000; Sigma, St. Louis, MO).
2.5. Histology
Six- and 12-month-old wild-type (+/+) and H67D/H67D mice
(n=4/genotype) were perfused transcardially with Ringer's solution
followed by ice-cold 4% paraformaldehyde. The brains were parafﬁn-
embedded and sectioned coronally at 6-μm-thick. The sections were
deparafﬁnized and then rehydrated through a series of ethanol.
After antigen retrieval with sodium citrate (pH 6), endogenous per-
oxidase activity was blocked with hydrogen peroxide (3.7% in meth-
anol) for 20 min at room temperature. The sections were then
blocked for 1 h with 2% milk and were incubated with primary anti-
bodies overnight at 4 °C followed by 1 h of incubation at room tem-
perature with biotinylated anti-host secondary antibody (1:200;
vector laboratories, Burlingame, CA). Immunoreactivity was detected
using the avidin biotin complex (ABC) and 3,3′-diaminobenzidine
(DAB; vector laboratories, Burlingame, CA). The sections were ana-
lyzed with a bright-ﬁeld microscopy by an investigator blinded for
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staining: L-ferritin (1:250; abcam, Cambridge, MA), transferrin recep-
tor (1:250; Zymed Laboratories Inc., San Francisco, CA), divalent
metal transporter-1 (1:200; convence, Princeton, NJ) and transferrin
(1:200; MP biomedicals, Solon, OH).
For immunoﬂuorescence, after overnight incubation with rabbit
anti-GFAP antibody (1:1000; Dako, Carpinteria, CA) or rabbit Iba-1
antibody (1:600; Wako, Richmond, VA), sections were probed with
Alexa Flour 488 secondary antibody (Invitrogen, Grand Island, NY)
for 1 h in the dark at room temperature. After washes, slides were
mounted and the sections were analyzed with ﬂuorescence microsco-
py. For double immunoﬂuorescence staining, because both L-ferritin
and Iba-1 antibodies were made from the same host we ﬂuorescently
labeled L-ferritin using a DyLight 550 antibody labeling kit (Thermo
ﬁsher scientiﬁc, Waltham, MA) prior to the incubation with brain sec-
tions. The sections were ﬁrst incubated overnight with rabbit Iba-1
antibody followed by overnight incubation with DyLight 550 labeled
L-ferritin. The sections were then probed with Alexa Flour 488 sec-
ondary antibody for 1 h in the dark at room temperature. After
washes, the slides were mounted and the sections were analyzed
with ﬂuorescence microscopy.
2.6. Myelin isolation and analysis of myelin protein
Brain samples from 6- and 12-month-old mice (5 to 6/genotype)
were weighed and homogenized with 1.5 ml of 0.32 M sucrose.
After adding 2 ml of 0.85 M sucrose samples were centrifuged for
30 min at 41,000 rpm at 4 °C. The supernatant was discarded; the
middle layer was collected and resuspended with 2.5 ml iron free
water (Sigma, St. Louis, MO). The samples were centrifuged for
15 min at 41,000 rpm at 4 °C. Supernatant was discarded and the pel-
let was resuspended with 3.0 ml iron free water. The samples were
centrifuged 10 min at 17,000 rpm at 4 °C and collected the pellet,Fig. 1. Increased body weight and hepatic iron concentration in H67D knock-in mice. (A) G
followed by digestion with BspHI restriction enzyme to detect the H67D point mutation.
digested with BspHI from+/H67D mice results 500, 240 and 260 bp and DNA digested with
of age in three groups. At both ages, body weight of H67D/H67D mice is higher compared t
n=14 to 36 per genotype for each age group). (C) Total iron concentration measured
12-month-old H67D/H67D mice compared to the wild-type (+/+) mice. Hepatic iron co
for both age groups. Bars represent mean±standard error. * represents a signiﬁcant differ
(pb0.05). n=4 to 9 per genotype.which was crude myelin protein. The pellets were kept at −80 °C
for 20 min and then were freeze-dry using a lyophilizer overnight.
The pellets were then left at room temperature for 20 min and were
weighed. The pellets were resuspended with RIPA buffer (Sigma, St.
Louis, MO) and centrifuged 45 min at 51,000 rpm at 4 °C. Superna-
tant was collected and protein concentration was determined with
Pierce BCA protein assay kit (Thermo scientiﬁc, MA). Total protein
of 10 μg was used for immunoblot analyses to determine the expres-
sion of myelin basic protein (MBP; 1:1000; abcam, Cambridge, MA),
proteolipid protein (PLP; 1:1000; Millipore, Billerica, MA) and CNPase
(1:500; abcam, Cambridge, MA).
2.7. Measurement of oxidatively modiﬁed proteins
As a consequence of oxidative modiﬁcation to proteins, carbonyl
groups are introduced to the side chain of amino acids. These carbonyl
groups hallmark the oxidative status of protein [30]. An Oxyblot kit
(Millipore, Billerica, MA) was used to measure protein carbonyl levels.
Brieﬂy, total brain homogenates (20 μg) from 6- and 12-month-old
wild-type, +/H67D and H67D/H67D mice (6/genotype) were reacted
with 2,4-dinitrophenylhydrazone (DNP-hydrazone). Samples were
then treated according to the manufacturer's protocol.
2.8. Statistical analyses
Data were expressed as mean±standard error. An analysis of var-
iance (one-way ANOVA; GraphPad Prism 4) followed by a Tukey mul-
tiple comparison or Dunnett test was used to compare between
experimental groups. For iron measurement, two-way ANOVA was
performed to analyze the interaction of age and genotype with iron
concentration. Bonferroni posttest was used to compare between ex-
perimental parameters. A value of pb0.05 was considered signiﬁcant
for all experiments.eneration of H67D knock-in mice. PCR analysis of DNA obtained from tail biopsies was
DNA digested with BspHI from wild-type mice (+/+) results 240 and 260 bp; DNA
BspHI from H67D/H67D results 500 bp. (B) Body weight was taken at 6 and 12 months
o the wild-type mice. Bars represent mean±standard error. (*=pb0.05, **=pb0.01;
by atomic absorption spectrometry is 67% and 70% increase in the liver of 6- and
ncentration in H67D/H67D mice is 65% and 64% increase compared to +/H67D mice
ence from wild-type (pb0.05) and # represents a signiﬁcant difference from +/H67D
Fig. 2. Total brain iron concentration is altered in H67D/H67D mice. Total brain iron was
measured with atomic absorption spectrometry in 6- and 12-month-old mice. Brain
iron concentration is 22% and 18.6% increase in H67D/H67D and +/H67D compared to
wild-type (+/+) mice at 6 months (p=0.26). At 12 months of age, brain iron level in
H67D knock-in mice is not signiﬁcantly different from the wild-type mice. Analysis of
brain iron level by age indicates wild-type and +/H67D mice have increased brain iron
with age (32.9% and 26.5% respectively). Brain iron level is increased only 6.5% in
12-month-old H67D/H67Dmice compared to 6-month-old H67D/H67Dmice. Bars repre-
sent mean±standard error. (n=4 to 8 per genotype in both age groups).
Table 1
Summary ﬁndings from neurological characterization of the H67D mice.
Proteins Total expression level in the brain
(relative to wild-type)
6-month-old
H67D mice
12-month-old
H67D mice
Iron 22% ↑ Not different
HFE ↑ Not different
H-ferritin ↑ ↑
L-ferritin Not different ↑
Transferrin receptor Not different Not different
Transferrin Not different ↓
Divalent metal transporter-1 40% ↓ Not different
Tim-2 Not different ↓
Myelin proteins Not different Not different
Iba-1 (microglia) Not different ↑
GFAP ↑ Not different
Oxidatively modiﬁed proteins ↑ Not different
Cystine/glutamate transporter (xCT) ↑ Not different
Hemeoxygenase-1 (HO-1) ↑ Not different
Nrf2 Not different ↑
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3.1. Generation of H67D mice
A H67D knock-in mouse line (mouse homolog of the human
H63D) was generated by site-directed mutagenesis to murine HFE
gene. The resultant heterozygous mice were bred to generate wild-
type, heterozygous and homozygous H67D knock-in mice. Mice
carrying the H67D variant were indistinguishable at birth from their
littermate controls. Homozygous H67D mice develop normally and
are reproductively viable. Genotyping of mice was performed by
PCR analysis of DNA obtained from tail biopsies and subsequent
digestion with BspHI restriction enzyme (Fig. 1A). Body weights of
mice were taken at 6 and 12 months of age. At both ages, H67D/H67D
mice had signiﬁcantly higher body weight than wild-type mice while
the heterozygous H67D (+/H67D) mice had similar body weight as
the wild-type (Fig. 1B).
To conﬁrm whether the allelic variant is functional we determined
hepatic iron levels in 6- and 12-month-old H67D mice. Compared to
the wild-type mice, 6- and 12-month-old H67D/H67D mice had a
67% (266.4±27.3 vs. 159.6±31.9 μg/g of liver) and 70% (281.35±
50.7 vs. 165.7±22.9 μg/g of liver) increase in hepatic iron concentration
while+/H67Dmice had similar hepatic iron concentration aswild-type
mice at both ages (Fig. 1C). Six and 12-month-old H67D/H67D mice
also had changes in iron management protein expressions in the liver.
Consistent with increased iron concentration iron storage proteins,
H-ferritin and L-ferritin were signiﬁcantly increased while iron trans-
port protein transferrin receptor (TfR) was signiﬁcantly decreased in
H67D/H67Dmice compared to wild-typemice at both ages. Ceruloplas-
min,which is involved in iron export,was also signiﬁcantly decreased in
12-month-old H67D/H67D mice compared to the wild-type (Supple-
mentary Fig. 1). Together these results indicated that the allelic variant
is functional in H67D mice.
3.2. Brain iron concentration in H67D mice
Total brain iron was measured in 6- and 12-month-old mice by
atomic absorption spectrometry. At 6 months of age, total brain ironFig. 3. Altered iron management protein expressions in H67D knock-in mice. (A–L) Brain hom
determined for the presence of HFE, H-ferritin, L-ferritin, transferrin, divalent metal transpo
Western blot. A representative Western blot is shown for each protein and quantiﬁcatio
At 6 months of age, HFE (A) and H-ferritin expression is increased (C) while DMT-1 expre
(G) and Tim-2 expressions (K) are not signiﬁcantly changed in H67D knock-in mice. At 12
ferrin (H) and Tim-2 expressions (L) are decreased in H67D/H67D compared to +/+ mic
Bars represent mean±standard error. * represents a signiﬁcant difference from wild-type (*=
##=pb0.01; ###=pb0.001; n=4 to 6 per genotype).level was 22% higher in H67D/H67D (22.57±2.0 μg/g of brain) and
18.6% higher in +/H67D mice (21.95±1.4 μg/g of brain) compared
to wild-type mice (18.5±0.7 μg/g of brain) although these differ-
ences did not reach statistical signiﬁcance (p=0.26). At 12 months
of age, total brain iron concentration in H67D/H67D mice (24.04±
1.1 μg/g) and+/H67Dmice (27.76±3.0 μg/g) was not different com-
pared to wild-type mice (24.58±1.4 μg/g). There was a signiﬁcant
interaction for age and iron concentrations indicating that regardless
of genotypes brain iron concentration increased with age (p=0.01).
Compared to 6-month-old mice, by 12 months, brain iron concentra-
tion increased by 33% in the wild-type, 26.5% in the +/H67D but only
6.5% in H67D/H67D mice (Fig. 2 and Table 1).
3.3. Alteration in expression of proteins involved in iron homeostasis in
H67D mice
Although total iron levels are important, it is the response of the
regulatory proteins that are perhaps most important because they
maintain homeostasis. Thus, we evaluated the expressions of proteins
involved in brain iron homeostasis: HFE, H-ferritin, L-ferritin, trans-
ferrin receptor (TfR), transferrin (Tf), divalent metal transporter-1
(DMT-1) and T cell immunoglobulin and mucin domain-containing
protein-2 (Tim-2). Western blot analyses of brain homogenates
from 6- and 12-month-old mice revealed differences in the levels of
iron management proteins in H67D/H67D mice compared to the
wild-type (Table 1 and Fig. 3). At 6 months, H67D/H67D mice had
signiﬁcant increases in HFE (Fig. 3A) and H-ferritin (Fig. 3C) and a
40% decrease in DMT-1 which did not reach statistical signiﬁcance
(p=0.07; Fig. 3I). L-ferritin, Tf, Tim-2 levels (Fig. 3E, G, K) and TfR
(data not shown) in H67D/H67D mice were not different from
wild-type mice. At 12 months of age, H67D/H67D mice had increases
in H- and L-ferritin levels (Fig. 3D, F), and decreases in Tf (Fig. 3H)
and Tim-2 levels (Fig. 3L) compared towild-typemice. The relative con-
centrations of HFE, DMT-1 (Fig. 3B, J) and TfR (not shown) in H67D/
H67D mice were not different from wild-type mice at this age. None
of the iron management proteins levels in +/H67Dmice were different
from wild-type at any ages (Fig. 3A–L).ogenates from 6- and 12-month-old wild-type (+/+), +/H67D and H67D/H67D were
rter-1 and T cell immunoglobulin and mucin domain-containing protein-2 (Tim-2) by
n of blots is shown as bar graphs. The expression level was normalized to β-actin.
ssion is tended to decrease (I; p=0.07) in H67D/H67D mice. L-ferritin (E), transferrin
months of age, H-ferritin (D) and L-ferritin (F) expressions are increased while trans-
e. HFE (B) and DMT-1 expressions (J) in H67D/H67D mice do not alter signiﬁcantly.
pb0.05; **=pb0.01). # represents a signiﬁcant difference from +/H67D (#=pb0.05;
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DMT-1, transferrin and L-ferritin by immunohistochemical staining in
both age groups. At the cellular level, transferrin receptor (TfR) staining
was primarily conﬁned to neurons with very little or no TfR staining in
the white matter tracts in either group. There appeared to be regional
differences in staining for TfR at 6 months; compared to wild-type
mice, H67D/H67Dmice hadweaker neuronal staining for TfR in the cor-
tex (Fig. 4A–B) and the cerebellum (data not shown) but stronger TfR
staining in the striatum (Fig. 4C–D). Immunohistochemical analysis
for DMT-1 revealed that similar cell types were stained for DMT-1 pro-
tein in both groups (Fig. 5). However, compared to wild-type mice
(Fig. 5A, C, E), 6-month-old H67D/H67D mice had relatively weaker
neuronal staining for DMT-1 in the cortex (Fig. 5B) and the purkinje
cells of cerebellum (Fig. 5F), and weaker staining in oligodendrocytes
in the striatum (Fig. 5D). The DMT-1 immunostaining was not different
between 2 groups at 12 months (data not shown), which is consistent
with immunoblot analysis. For transferrin, the same type of cells was
positive for staining in both wild-type and H67D/H67D mice. Neuronal
transferrin staining was observed in the cortex (Fig. 6A, B) while trans-
ferrin stainingwas foundpredominantly in oligodendrocytes in the stri-
atum and corpus callosum (Fig. 6C–F). Staining intensity for transferrin
was much less in H67D/H67D (Fig. 6B, D, F) compared to wild-type mice
in all regions examined at 12 months (Fig. 6A, C, E). Higher L-ferritin
staining intensity was seen only in 12-month-old H67D/H67D mice
compared to wild-type mice, which is consistent with immunoblot
analysis. L-ferritin staining was found primarily in the glial cells,
although there was relatively weak neuronal staining in the cortex of
H67D/H67D (Fig. 7A–B). L-ferritin staining was primarily found in
the oligodendrocytes in the striatum and thalamus (Fig. 7C–F) in
both groups; however, there was more robust L-ferritin staining in
H67D/H67D mice (Fig. 7B, D, F) compared to the wild-type mice
(Fig. 7A, C, E).
To determine whether L-ferritin positive glial cells observed in the
cortex were either astrocytes or microglia, we performed double
immunoﬂuorescence staining. The ﬂuorescence analysis also reveals
an increase L-ferritin staining in 12-month-old H67D/H67D mice
and strong co-localization of L-ferritin with Iba-1 positive microgliaFig. 4. Immunohistochemical localization for transferrin receptor (TfR). Neurons in the cortex o
weaker in H67D/H67D mice. In striatum, TfR staining is primarily conﬁned to neurons in both
wild-type, H67D/H67D mice have relatively higher staining intensity for TfR in the striatum (C(Fig. 8 and Table 1). There also appeared to be an increase in number
of Iba-1 positive microglia and L-ferritin immunoreactive microglia in
12-month-old H67D/H67D indicating the presence of microgliosis in
H67D mice (Fig. 8E, F). However, the number of microglia in H67D
mice at 6 months did not differ from wild-type mice (Supplementary
Fig. 2 and Table 1). L-ferritin did not co-localize with GFAP positive
astrocytes (Supplementary Fig. 3).
3.4. Myelin proteins were not changed in H67D mice
Crude myelin protein was extracted by sucrose gradient and ultra-
centrifugation and three major myelin proteins in myelin extract
were analyzed in 6- and 12-month-old mice by immunoblotting.
Myelin basic protein (MBP), proteolipid protein (PLP) and CNPase
protein were not changed signiﬁcantly between any of the groups
at either age (Supplementary Fig. 4A–F and Table 1).
3.5. H67D HFE is associated with astrogliosis
To determine whether H67D HFE is associated with increased
gliosis, we evaluated GFAP staining in H67D mice at both ages
(Fig. 9 and Table 1). GFAP staining was increased in all observed
brain regions; the cortex, hippocampus and the cerebellum in
6-month-old H67D/H67D (Fig. 9D, F, H, J) compared to wild-type
mice (Fig. 9C, E, G, I), which is consistent with the signiﬁcant increase
in total GFAP level in H67D knock-in mice determined by immunoblot-
ting (Fig. 9A). GFAP staining and total GFAP level in 12-month-oldH67D
mice was not changed signiﬁcantly from wild-type mice (Fig. 9B, K–R).
3.6. H67D HFE is associated with oxidative stress
Because H63D HFE is associated with higher baseline stress in our
cell models [23], we determined the level of oxidatively modiﬁed pro-
teins (carbonyl level), and expression of xCT antiporter, which is
essential for maintaining intracellular glutathione level [31], and
hemeoxygenase-1 (HO-1; [32]) as indices of oxidative stress in
H67D mice. The level of oxidatively modiﬁed proteins increased inf both wild-type (+/+) and H67D/H67Dmice express TfR (A, B); however TfR staining is
groups with little or no TfR staining is observed in the white matter tract. Compared to
, D). A scale bar represents 50 μm. n=4 per genotype.
Fig. 5. Immunohistochemical localization for divalent metal transporter-1(DMT-1). Neurons in the cortex of both wild-type (+/+) and H67D/H67D mice express DMT-1 with
much less DMT-1 staining is observed in H67D/H67D mice compared to wild-type mice (arrows in A, B). In striatum, DMT-1 expresses predominantly in oligodendrocytes (arrows
in C, D). Blood vessels staining for DMT-1 are also observed in both wild-type and H67D/H67D mice; however, the staining intensity is relatively weaker in H67D mice (arrow head
in C, D). In cerebellum, strong neuronal staining for DMT-1 is observed in Purkinje cells in wild-type mice (arrows in E). In contrast, Purkinje cells of cerebellum in H67D/H67Dmice
have relatively little staining for DMT-1 (arrows in F). bv=blood vessel. A scale bar represents 50 μm. n=4 per genotype.
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compared to the wild-type (Fig. 10A and Table 1). Moreover, xCT ex-
pression was 86% higher and HO-1 expression was 27% higher in the
brains of 6-month-old H67D/H67D mice compared to the wild-type
mice (Fig. 10C, E and Table 1). However, there was no difference inFig. 6. Immunohistochemical localization for transferrin. Neurons in the cortex of both wild-
positive oligodendrocytes are observed in the cortex (arrow head in A, B). However, transfe
corpus callosum (arrows in E, F) of both wild-type and H67D/H67D mice. Transferrin positi
few of process bearing oligodendrocytes staining for transferrin are present (arrow heads
compared to the wild-type mice. LV=lateral ventricle; bv=blood vessel. A scale bar reprethe oxidatively modiﬁed proteins level, and xCT and HO-1 expression
between three groups at 12 months of age (Fig. 10B, D, F and Table 1).
To examine whether an increase oxidative stress observed in
6-month-oldH67Dmice, is associatedwith an impaired cellular defense
system against redox stress we measured the expression of nucleartype (+/+) and H67D/H67D mice express transferrin (arrows in A, B). Few transferrin
rrin expresses predominantly in oligodendrocytes in the striatum (arrows in C, D) and
ve oligodendrocytes appear in a row in the corpus callosum (arrows in E, F) and only a
in E, F). In all observed regions, transferrin staining is much less in H67D/H67D mice
sents 50 μm. n=4 per genotype.
Fig. 7. Immunohistochemical localization for L-ferritin. L-ferritin staining in the cortex is relatively weak in both wild-type (+/+) and H67D/H67D mice. The staining is mostly
conﬁned to glial cells (arrows in B). L-ferritin staining in the striatum (arrows in C and D) and the thalamus (E–F) is primarily conﬁned to oligodendrocytes. L-ferritin staining
in the cortex, striatum and the thalamus is relatively weak in wild-type mice (A, C, and E). In contrast, L-ferritin staining is more robust with more L-ferritin-positive oligodendro-
cytes in H67D/H67D mice (B, D, and F). A scale bar represents 50 μm. n=4 per genotype.
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oxidant genes transcription. The expression of Nrf2 in 6-month-old
H67D/H67D and +/H67D mice was not different from wild-type mice
(Fig. 11A and Table 1) but was 69% higher (pb0.05) in 12-month-old
H67D/H67D mice compared to the wild-type (Fig. 11B and Table 1).Fig. 8. Double immunostaining showing the co-localization of L-ferritin and Iba-1. Double ﬂu
the glial cells in the cortex of both wild-type (+/+) and H67D mice (A, D); however there
indicate the co-localization of L-ferritin with Iba-1 positive microglia to greater extent (C
compared to the wild-type (B, C). A scale bar represents 50 μm. n=4 per genotype.4. Discussion
Because liver iron accumulation is a common histologic ﬁnding
and perhaps the gold standard for diagnosis of HFE associated hemo-
chromatosis we ﬁrst determined the liver iron concentration in H67Dorescence analysis indicates that L-ferritin ﬂuorescence staining is present primarily in
are increased number of L-ferritin positive glial cells in H67D mice (D). Merged images
, F). More L-ferritin positive microglia is observed in the cortex of H67D mice (E, F)
Fig. 9. Increased GFAP in 6-month-old but not in 12-month-old H67D knock-in mice. (A, B) GFAP protein expression was determined in brain homogenates from 6- and
12-month-old mice. Quantiﬁcation of blots is shown as bar graphs. The expression level was normalized to β-actin. At 6 months, the +/H67D and H67D/H67D mice have signiﬁcant
increase in GFAP protein expression compared to +/+mice. Total brain GFAP expression in 12-month-old +/H67D and H67D/H67D mice did not change signiﬁcantly compared to
+/+ mice. Bars represent mean±standard error. (*=pb0.05; **=pb0.01; n=5 to 6 per genotype). (C–J) Immunoﬂuorescence analyses of GFAP in brains of 6-month-old mice
indicates that GFAP immunoreactivity is increased in the cortex (D), hippocampus (F and H) and cerebellum (J) of H67D/H67D compared to +/+ mice (C, E, G and I) (n=4 per
genotype). (K–R) Immunoﬂuorescence analyses of GFAP in brains of 12-month-old mice indicates that GFAP immunoreactivity in the cortex (L), hippocampus (N and P) and
cerebellum (R) of H67D/H67D mice is not different compared to +/+ mice (K, M, O and Q) (n=4 per genotype).
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elevated in both 6- and 12-month-old H67D/H67D mice, which is con-
sistent with the previous report of Tomatsu et al. [28] for 10-week-old
H67Dmice. H67D/H67Dmice also had signiﬁcant alterations in expres-
sion of liver iron management proteins such as increased storage pro-
teins while decreased transport proteins. Changes in liver iron proﬁles
in H67D mice indicate that the H67D allelic variant is functional in
these mice. Although H67D mice are indistinguishable from wild-typemice at birth, H67D/H67D mice have increased weight gain with age.
Increased body weight together with higher hepatic iron concentration
in H67Dmicemay be relevant to the increased prevalence of metabolic
syndrome including obesity that is positively associated with elevated
iron stores and increased serum ferritin levels [33–36]. Thus, the utility
of this model could extend beyond studies directly involving the ner-
vous system and have relevance to studies on HFEmutations in general.
Because HFE polymorphisms are common allelic variants in Caucasians,
Fig. 10. Increased oxidative stress in H67D knock-in mice. An oxyblot assay and slotblot analysis was used to measure total oxidatively modiﬁed protein levels in 6-month-old and
12-month-old mice. (A and B). Total oxidatively modiﬁed protein levels is signiﬁcantly higher in 6-month-old +/H67D (50%) and H67D/H67D (64%) compared to wild-type (+/+)
mice (A). By 12 months, total oxidatively modiﬁed protein levels in H67D mice do not change signiﬁcantly compared to +/+ mice (B). Brain homogenates from 6- and
12-month-old wild-type (+/+), +/H67D and H67D/H67D were determined for the expression of cystine/glutamate antiporter (xCT) that is essential for maintaining intracellular
glutathione level and hemeoxygenase-1 (HO-1). A representative Western blot is shown and quantiﬁcation of blots is shown as bar graphs. The expression level was normalized to
β-actin. The expression of xCT and HO-1 in 6-month-old H67D/H67D is increased by 86% and 27% respectively compared to the wild-type (+/+) mice (C, E). Brain xCT and HO-1
expression level in H67D/H67D and +/H67D mice is not signiﬁcantly different compared to the wild-type (+/+) mice at 12 months (D, F). Bars represent mean±standard error.
(*=pb0.05; **=pb0.01; ***=pb0.001; n=5 to 6 per genotype).
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aging and diseases.
This model differs from previous investigations that used HFE
knockout mice into the association between HFE and brain iron accu-
mulation. Although both our model and the knockout model accumu-
late iron in the liver [28,37], only our H67D knock-in model showed
brain iron accumulation. However, the HFE knockout mice were ex-
amined at an earlier age than ours [38,39]. Our model with an analo-
gous HFE mutation (H67D HFE) is more similar to the human
condition and MRI studies [14–16] and early histological studies
[12,13] that report increased iron in the brain in association with
HFE mutations. The presence of the HFE mutation is associated withmultiple changes in cells and animal models, including ER stress
[24] and cholesterol disruption [40] which suggest the HFE mutant
protein may impact the cell phenotype beyond iron uptake.
Our study evaluated brain iron proﬁles in H67D knock-in mice at 6
and 12 months of age. Brain iron was increased by 22% in H67D mice,
but this was not statistically signiﬁcant. However, there was in-
creased expression of iron storage protein H-ferritin at both ages as
well as an increase in L-ferritin at 12 months in the H67D mice.
These ﬁndings are strong indication that the increased amount of
brain iron in H67D mice was biologically meaningful and suggest
brain iron metabolism is altered in these mice. Perhaps the most im-
pressive evidence for altered brain iron homeostasis in H67D mice is
Fig. 11. H67D HFE increases Nrf2 expression. Brain homogenates from 6- and
12-month-old wild-type (+/+), +/H67D and H67D/H67D were determined for the
expression of nuclear factor E2-related factor 2 (Nrf2) that controls the endogenous
anti-oxidant genes transcription in response to redox stress. A representative Western
blot is shown and quantiﬁcation of blots is shown as bar graphs. The expression level
was normalized to β-actin. (A) The expression of Nrf2 in 6-month-old H67D/H67D
and +/H67D mice is not different signiﬁcantly from wild-type (+/+) mice. (B) Brain
Nrf2 expression level is increased in 12-month-old H67D/H67D mice compared to
the wild-type mice. Bars represent mean±standard error. (*=pb0.05; n=5 to 6
per genotype in both age group).
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datively modiﬁed proteins, and increased expression of xCT and
HO-1. Of note, is that the consequences of loss of iron homeostasis
(increased oxidative stress and astrogliosis) are manifested in the
brains of the 6-month-old mice but not at 12 months. The lack of ox-
idative stress in 12 months of age could be the result of an apparent
adaptive response to the oxidative stress mediated by Nrf2 which
was elevated in the 12-month-old H67D mice.
In addition to the increase in Nrf2 as an adaptive response, there are
multiple adaptive responses by the iron management proteins. At
6 months, H67D mice have increased H-ferritin which is involved in
rapid iron uptake and iron detoxiﬁcation [41,42], and a regional de-
crease in TfR, which delivers iron to neurons [43,44]. The expression
of ferritin and TfR are regulated post-transcriptionally according to
iron status. Iron overload increases ferritin protein synthesis while
decreases TfR protein synthesis [10]. Thus, increased H-ferritin is con-
sistent with increased iron concentration in H67D mice. Although we
expected a decrease in TfR expression, total TfR expression in H67D
mice was not different from wild-type mice. At cellular level however,
we found regional differences in TfR staining in H67D mice with rela-
tively weaker in the cortex and cerebellum but increased TfR staining
in the striatum compared to the wild-type. Regional differences in TfR
expression have been reported by Dornelles et al. [45] who demonstrat-
ed that iron loading decreased TfR mRNA in the cortex and hippocam-
pus while it increased TfR mRNA in the striatum. Regional differences
in TfR expressionmay be associatedwith heterogeneity of iron distribu-
tion in the brain [46,47]. In all brain regions examined, we found that
TfR staining was primarily conﬁned to neurons in both groups which
are consistent with previous studies [43,44,48].Transferrin, the major iron mobilization protein, is 39% decreased
in H67D mice. Because transferrin is synthesized primarily by the ol-
igodendrocytes [49] reduced transferrin may suggest decreased met-
abolic activity by oligodendrocytes. However, transferrin is also taken
up by the brain [50,51] and iron overload lowers transferrin uptake
by the brain [50]. Decreased transferrin levels are also associated
with aging and brain disease [52]. Together these data suggest
lower transferrin levels in H67D mice would decrease iron mobiliza-
tion and limit iron delivery particularly to neurons. The other iron de-
livery protein in the brain, Tim-2 is decreased in 12-month-old H67D
mice. Tim-2 is a receptor for H-ferritin on oligodendrocytes and its
expression is inversely related to iron status [53]. Therefore, de-
creased Tim-2 expression in H67D mice is an additional response to
decrease iron availability. Despite the decrease in transferrin and
Tim-2, myelin proteins expression is normal but total brain cholester-
ol is decreased [40]. Cholesterol is expressed by neurons as well as
found in myelin, thus further analysis of myelin in the presence of
the HFE gene variants is warranted particularly in light of the diffu-
sion weighted imaging (DWI) analysis by Jahanshad et al. [19]
suggesting that H63D HFE is associated with increased myelin
integrity.
An additional compensatory response indicating increased iron
availability in the brain is the 40% decrease in DMT-1 levels in
6-month-old H67D mice. DMT-1 transports iron out of the endosome
to the cytosol of the endothelial cell and is down-regulated with in-
creased iron availability. DMT-1 is found in brain endothelial and
ependymal cells, and a mutation in DMT-1 led to less detectable
iron in both neurons and glia [54,55]. In H67D mice, DMT-1 staining
is lower in the cortex, striatum and cerebellum suggesting that cells
are exposed to increased iron. Further evidence for altered brain
iron homeostasis in 12-month-old H67D mice is a 2-fold increase in
L-ferritin, which involves in long-term iron storage [56]. Increased
L-ferritin staining is found in microglia and neurons; the latter
being visible but weak. Although L-ferritin is primarily found in glial
cells [57], neurons have capacity to express L-ferritin when chal-
lenged with iron [58]. Therefore, the presence of L-ferritin positive
microglia and neurons in H67D mice suggests the initiation of adap-
tive responses and that microglia increases iron storage as an attempt
to effectively manage the iron that has accumulated in the brain.
An additional change in glia in the H67Dmice is the increased GFAP
expression throughout the brain at 6 months indicating astrogliosis. Re-
active gliosis is a rapid response to CNS injury andmetabolic stress [59];
thus, increased GFAP expression indicates that cellular metabolic
stress occurs in the brains of 6-month-old H67D mice. However, at
12 months, there is no longer increased cellularmetabolic stress and in-
dicates that the adaptive mechanisms to protect against iron-induced
toxicity were successful. However, the metabolic disruptions as conse-
quences of the altered iron status were not completely restored given
the ﬁnding of persistent alterations in cholesterol metabolism and
behaviors [40] and increased ER stress [24] in the H67D mice.
In summary, there are two salient ﬁndings in this study. Firstly, we
provide the direct in vivo evidence that H63D HFE impacts brain iron
homeostasis and creates environment for oxidative stress. Our ﬁnd-
ings together with recent MRI studies [14–17] shift the existing clas-
sical paradigm that brain is protected from iron overload associated
with HFE mutations. Secondly, we demonstrated that as they age,
H67D mice appear to develop adaptive mechanisms such as elevated
Nrf2, decreased iron mobilization via Tf, and increased iron storage
within L-ferritin that limits the amount of iron available to induce oxi-
dative stress. Although there are compensatorymechanisms at younger
ages, they are not sufﬁcient to protect the brain because 6-month-old
H67D mice have increased oxidative stress and astrogliosis. Moreover,
our ﬁndings suggest that H67D mice may be more susceptible to envi-
ronmental challenges and/or genetic modiﬁers at younger ages when
there is a stress milieu and gliotic responses trying to adapt to the met-
abolic stress. The presence of oxidative and cellular stress in brains of
740 W. Nandar et al. / Biochimica et Biophysica Acta 1832 (2013) 729–741H67Dmice support our hypothesis that H63D HFE establishes an envi-
ronment for pathogenic factors that promote cellular damage and
neurodegeneration. For example, a double transgenic mouse line that
carries both SOD1(G93A)mutation and the H67D gene variant have ac-
celerated disease progression and shorter survival than SOD1(G93A)
ALS mouse model [60]. Thus, these data strongly indicate that the
H67D mouse line presented here can be used as a model to evaluate
how H63D HFE contributes to disease mechanisms and its impacts on
the treatment strategies in neurodegenerative diseases.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.02.009.Abbreviations
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